Delphi advisor to Immunicum in connection with listing on Nasdaq Stockholm Small Cap

Immunicum is a biotechnology company advancing a novel immuno-oncology treatment against a range of solid tumors. The company aims to advance therapeutic cancer treatments at least through clinical phase II trials and then license the product candidates to major pharmaceutical or biotech companies.

For more information, see Immunicum’s press release: www.imminicum.se

Delphi’s team consisted mainly of responsible partner Mats Dahlberg, Jonas Ingvarsson and Jenny Lindén. In addition, a large number of Delphi lawyers have been involved in the work.